Xience V

DEVICE4 trials

Sponsors

Seung-Jung Park, Shanghai MicroPort Medical (Group) Co., Ltd., Shandong Branden Med.Device Co.,Ltd

Conditions

Coronary Artery DiseaseCoronary Artery Stenosis

Phase 3

Cordimax China Post Market Surveillance

Shandong Branden Med.Device Co.,LtdCoronary Artery Stenosis

Start: 2013-06-20End: 2020-06-20Updated: 2017-06-14

Phase 4

Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus

CompletedNCT00997763

Seung-Jung ParkCoronary Artery Disease

Start: 2008-07-31End: 2015-08-31Updated: 2016-12-13

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)

CompletedNCT01078038

Seung-Jung ParkCoronary Artery Disease

Start: 2008-06-30End: 2010-08-31Updated: 2012-08-08

Unknown Phase

Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial

CompletedNCT01196819

Shanghai MicroPort Medical (Group) Co., Ltd.Coronary Artery Disease

Start: 2010-09-30End: 2016-12-31Updated: 2019-07-30

Related Papers

Comparison of Different Types of Drug-Eluting Stents for De Novo Long Coronary Artery Lesions

JACC Asia2022-05-247 citations

[Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions].

PubMed2017-11-243 citations

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.

2013-05-0155 citations